MX343327B - Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. - Google Patents

Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.

Info

Publication number
MX343327B
MX343327B MX2013009570A MX2013009570A MX343327B MX 343327 B MX343327 B MX 343327B MX 2013009570 A MX2013009570 A MX 2013009570A MX 2013009570 A MX2013009570 A MX 2013009570A MX 343327 B MX343327 B MX 343327B
Authority
MX
Mexico
Prior art keywords
tnfa
assays
present
autoantibodies
detecting autoantibodies
Prior art date
Application number
MX2013009570A
Other languages
English (en)
Spanish (es)
Other versions
MX2013009570A (es
Inventor
Singh Sharat
Long Wang Shui
Ohrmund Linda
Hauenstein Scott
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013009570A publication Critical patent/MX2013009570A/es
Publication of MX343327B publication Critical patent/MX343327B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013009570A 2011-02-17 2012-02-16 Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. MX343327B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161444097P 2011-02-17 2011-02-17
US201161484594P 2011-05-10 2011-05-10
US201161496501P 2011-06-13 2011-06-13
PCT/US2012/025437 WO2012154253A1 (en) 2011-02-17 2012-02-16 ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS

Publications (2)

Publication Number Publication Date
MX2013009570A MX2013009570A (es) 2013-09-06
MX343327B true MX343327B (es) 2016-11-01

Family

ID=45809635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009570A MX343327B (es) 2011-02-17 2012-02-16 Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.

Country Status (16)

Country Link
US (1) US20140045276A1 (cg-RX-API-DMAC7.html)
EP (1) EP2676137B1 (cg-RX-API-DMAC7.html)
JP (1) JP6063398B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140008397A (cg-RX-API-DMAC7.html)
CN (1) CN103502815B (cg-RX-API-DMAC7.html)
AU (1) AU2012254150B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013020981A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827609A1 (cg-RX-API-DMAC7.html)
DK (1) DK2676137T3 (cg-RX-API-DMAC7.html)
ES (1) ES2530175T3 (cg-RX-API-DMAC7.html)
IL (1) IL227853A (cg-RX-API-DMAC7.html)
MX (1) MX343327B (cg-RX-API-DMAC7.html)
RU (1) RU2013142278A (cg-RX-API-DMAC7.html)
SG (1) SG192770A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012154253A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306950B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281359B2 (en) 2013-05-17 2025-04-22 Cedars-Sinai Medical Center Variants of TNFSF15 and DCR3 associated with Crohn's disease

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
AU2011317149B2 (en) 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
SG10201605516YA (en) 2011-07-06 2016-08-30 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
JP6279590B2 (ja) 2012-10-03 2018-02-14 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 酸性条件でアナライトを測定するための方法およびキット
ES2638971T3 (es) 2012-10-05 2017-10-24 Nestec S.A. Métodos para predecir y monitorizar la cicatrización de la mucosa
BR112015012482A2 (pt) * 2012-11-30 2017-07-11 Nestec Sa ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
CA2908553A1 (en) 2013-03-27 2014-10-02 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
EP3654037A1 (en) 2013-12-03 2020-05-20 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
EP3667321B1 (en) 2014-02-11 2022-07-27 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
AU2015240454B2 (en) 2014-04-04 2019-08-22 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN104034896A (zh) * 2014-06-19 2014-09-10 华北制药集团新药研究开发有限责任公司 一种双抗体夹心elisa检测方法
WO2016018978A1 (en) * 2014-07-29 2016-02-04 Mayo Foundation For Medical Education And Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
MX2017004742A (es) * 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
EP3736575B1 (en) * 2014-11-05 2024-08-28 F. Hoffmann-La Roche AG Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody
EP3227683B1 (en) 2014-12-05 2019-04-24 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
JP6968058B2 (ja) 2015-09-24 2021-11-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 質量分析法による免疫グロブリン遊離軽鎖の同定
ES2815224T3 (es) * 2015-11-06 2021-03-29 Promise Proteomics Un método para cuantificar anticuerpos terapéuticos
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
US11119096B2 (en) 2016-07-08 2021-09-14 W. Health L.P. Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
WO2018047793A1 (ja) * 2016-09-06 2018-03-15 富士レビオ株式会社 腫瘍マーカーの測定方法及び測定試薬
WO2018049001A1 (en) 2016-09-07 2018-03-15 Mayo Foundation For Medical Education And Research Identification and monitoring of cleaved immunoglobulins by molecular mass
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
WO2019055634A1 (en) 2017-09-13 2019-03-21 Mayo Foundation For Medical Education And Research IDENTIFICATION AND MONITORING OF A MACROPHAGE APOPTOSIS INHIBITOR
WO2019105916A1 (en) * 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
CN112534263A (zh) * 2018-08-03 2021-03-19 百时美施贵宝公司 用于检测抗药抗体的方法
JP2022520382A (ja) 2019-02-11 2022-03-30 フェニックス モレキュラー デザインズ Ｒｓｋ阻害剤の結晶形態
JP2020115139A (ja) * 2020-03-11 2020-07-30 国立大学法人千葉大学 血管炎の検査方法
KR102562006B1 (ko) 2020-11-09 2023-08-02 바디텍메드(주) 항tnf-알파 약물 모니터링을 위한 신속 검출 키트
CN112362649B (zh) * 2020-11-09 2024-07-12 长春金赛药业有限责任公司 一种rhGH中和抗体的检测方法
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
CN114236139A (zh) * 2021-12-30 2022-03-25 苏州和锐生物科技有限公司 一种TNF-α生物制剂的抗体检测试剂盒、制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5094740A (en) * 1990-02-16 1992-03-10 Glycomed, Inc. Two-dimensional electrophoretic separation of carbohydrates
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
CA2364026C (en) * 1999-03-02 2012-08-21 Centocor, Inc. Anti-tnf.alpha. antibodies in therapy of asthma
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002036773A2 (en) 2000-10-30 2002-05-10 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
AU4341502A (en) 2000-10-30 2002-06-11 Univ Michigan Nod2 nucleic acids and proteins
EP1340078B1 (en) 2000-11-14 2009-05-27 Techlab, Inc. Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrin as a marker
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
CA2502976C (en) 2002-10-25 2012-05-22 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
EP1687447A4 (en) 2003-11-03 2008-04-02 Univ Duke METHOD FOR IDENTIFYING INDIVIDUALS IN THE HAZARD OF PERIOPERATIVE BLOODING, A KIDNEY PROBLEM OR A STROKE
EP1769244A4 (en) * 2004-06-30 2008-05-14 Dow Kenneth Centocor Inc DETECTION OR MEASUREMENT OF ANTIGEN PROTEIN ANTIBODIES IN BIOLOGICAL TISSUE OR SAMPLES
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
JP2007147367A (ja) * 2005-11-25 2007-06-14 Sekisui Chem Co Ltd サイトカイン産生能の測定方法
WO2008059515A2 (en) 2006-08-01 2008-05-22 Divyank Turakhia A system and method of generating related words and word concepts
RU2442171C2 (ru) 2006-09-21 2012-02-10 Промитьюс Лабораториз Инк. Чипы на основе антител для определения множественных трансдукторов сигналов в редких циркулирующих клетках
AU2008276251B2 (en) 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
US20110020840A1 (en) * 2008-01-15 2011-01-27 Gerrit Jan Wolbink Method and kits for detecting antibodies against therapeutic antibodies
EP2602623B1 (en) 2008-02-25 2015-09-16 Nestec S.A. Mehtod for the detection of intracellular truncated receptors
JP5634405B2 (ja) * 2008-10-07 2014-12-03 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ 試料中のアナライトの検出のための半逐次アッセイ
EP2430443B1 (en) 2009-05-14 2018-06-27 Pierian Holdings, Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US8408369B2 (en) 2009-09-08 2013-04-02 GM Global Technology Operations LLC Bimetallic brake rotor
CA2777934A1 (en) 2009-10-20 2011-04-28 Prometheus Laboratories Inc. Proximity-mediated assays for detecting oncogenic fusion proteins
NZ599456A (en) * 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281359B2 (en) 2013-05-17 2025-04-22 Cedars-Sinai Medical Center Variants of TNFSF15 and DCR3 associated with Crohn's disease

Also Published As

Publication number Publication date
IL227853A (en) 2017-07-31
HK1191688A1 (en) 2014-08-01
BR112013020981A2 (pt) 2016-10-11
EP2676137B1 (en) 2014-12-31
CN103502815B (zh) 2015-09-23
KR20140008397A (ko) 2014-01-21
EP2676137A1 (en) 2013-12-25
IL227853A0 (en) 2013-09-30
AU2012254150B2 (en) 2015-08-13
US20140045276A1 (en) 2014-02-13
AU2012254150A1 (en) 2013-05-02
ES2530175T3 (es) 2015-02-26
NZ614170A (en) 2015-04-24
CA2827609A1 (en) 2012-11-15
RU2013142278A (ru) 2015-03-27
ZA201306950B (en) 2015-04-29
DK2676137T3 (en) 2015-01-19
MX2013009570A (es) 2013-09-06
CN103502815A (zh) 2014-01-08
JP6063398B2 (ja) 2017-01-18
SG192770A1 (en) 2013-09-30
JP2014508930A (ja) 2014-04-10
WO2012154253A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
MX2012004877A (es) Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
PH12013500544A1 (en) Breast cancer diagnostics
BR112014031365A2 (pt) métodos de detectar doenças ou condições
NZ627443A (en) Biological markers for identifying patients for treatment with vegf antagonists
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX345230B (es) Metodos para diagnosticar patogenos de enfermedad infecciosa y su sensibilidad a farmacos.
MX343324B (es) Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
WO2013030578A3 (en) Method for detecting nucleosomes
MX349561B (es) Método para detectar nucleosomas que contienen variantes de histonas.
PH12013500889A1 (en) Improved algorithm for detection of diabetes
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
MX2015006852A (es) Ensayos para detectar autoanticuerpos neutralizantes para terapia biologica.
MX2013000674A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
NZ603780A (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
EP2573192A4 (en) METHOD AND KIT FOR DIAGNOSING DISEASE ASSOCIATED WITH AIM
WO2014052685A3 (en) Devices and methods for single cell analysis
GB201206977D0 (en) An enzyme detection device
IN2014DN08398A (cg-RX-API-DMAC7.html)
SG10201806729VA (en) Novel assay to detect human periostin
WO2015049390A3 (en) Kidney disease biomarker

Legal Events

Date Code Title Description
FG Grant or registration